Cargando…

GSK-3 and lysosomes meet in Alzheimer’s disease

Aberrant regulation of glycogen synthase kinase-3 (GSK-3) is implicated in Alzheimer’s disease (AD), but the mechanisms involved remain elusive. Our recent study shows that GSK-3 impairs lysosomal acidification and that inhibition of GSK-3 re-acidified lysosomes in brains of AD mice. This effect was...

Descripción completa

Detalles Bibliográficos
Autores principales:	Avrahami, Limor, Eldar-Finkelman, Hagit
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Landes Bioscience 2013
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3737746/ https://www.ncbi.nlm.nih.gov/pubmed/23940827 http://dx.doi.org/10.4161/cib.25179

Ejemplares similares

GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS
por: Eldar-Finkelman, Hagit, et al.
Publicado: (2011)

Mechanisms and Therapeutic Implications of GSK-3 in Treating Neurodegeneration
por: Rippin, Ido, et al.
Publicado: (2021)

Prospects in GSK-3 Signaling: From Cellular Regulation to Disease Therapy
por: Arciniegas Ruiz, Sara, et al.
Publicado: (2022)

GSK-3β Inhibition in Birds Affects Social Behavior and Increases Motor Activity
por: Moaraf, Stan, et al.
Publicado: (2022)

Glycogen Synthase Kinase-3 Inhibitors: Preclinical and Clinical Focus on CNS-A Decade Onward
por: Arciniegas Ruiz, Sara Melisa, et al.
Publicado: (2022)

Discovery and Design of Novel Small Molecule GSK-3 Inhibitors Targeting the Substrate Binding Site
por: Rippin, Ido, et al.
Publicado: (2020)

Physiological expression of mutated TAU impaired astrocyte activity and exacerbates β-amyloid pathology in 5xFAD mice
por: Farfara, Dorit, et al.
Publicado: (2023)

GSK3β N-terminus binding to p53 promotes its acetylation
por: Eom, Tae-Yeon, et al.
Publicado: (2009)

The GSK3 hypothesis of Alzheimer's disease
por: Hooper, Claudie, et al.
Publicado: (2008)

Inactivation of MAP kinase signalling in Myc Transformed Cells and Rescue by LiCl inhibition of GSK3
por: Al-Assar, Osama, et al.
Publicado: (2005)

GSK3 and Alzheimer’s Disease: Facts and Fiction…
por: Kremer, Anna, et al.
Publicado: (2011)

Protective effect of the APOE-e3 allele in Alzheimer's disease
por: de-Almada, B.V.P., et al.
Publicado: (2011)

Glioma and Alzheimer’s Disease
por: Lehrer, Steven
Publicado: (2018)

Super‐resolution analyzing spatial organization of lysosomes with an organic fluorescent probe
por: Wang, Lei, et al.
Publicado: (2022)

Levels of enzyme activities in six lysosomal storage diseases in Japanese neonates determined by liquid chromatography-tandem mass spectrometry
por: Mashima, Ryuichi, et al.
Publicado: (2016)

Lysosomal secretion of Flightless I upon injury has the potential to alter inflammation
por: Cowin, Allison J., et al.
Publicado: (2012)

Microvesicle delivery of a lysosomal transport protein to ex vivo rabbit cornea
por: Thoene, Jess G., et al.
Publicado: (2020)

Voxel-based Specific Regional Analysis System for Alzheimer’s Disease (VSRAD) on 3-tesla Normal Database: Diagnostic Accuracy in Two Independent Cohorts with Early Alzheimer’s Disease
por: Sone, Daichi, et al.
Publicado: (2018)

Role of glycogen synthase kinase 3 beta (GSK3β) in mediating the cytotoxic effects of the histone deacetylase inhibitor trichostatin A (TSA) in MCF-7 breast cancer cells
por: Alao, John P, et al.
Publicado: (2006)

Polymorphisms in the Cholinergic Receptors Muscarinic (CHRM2 and CHRM3) Genes and Alzheimer’s Disease
por: Chee, Lim Ya, et al.
Publicado: (2018)

The Peptide-Directed Lysosomal Degradation of CDK5 Exerts Therapeutic Effects against Stroke
por: Zhou, Ya-Fan, et al.
Publicado: (2019)

The histone modification H3K4me3 is altered at the ANK1 locus in Alzheimer's disease brain
por: Smith, Adam R, et al.
Publicado: (2021)

Some Biochemical Markers in Patients with Alzheimer’s Disease
por: KHANAHMADI, Mohammad, et al.
Publicado: (2016)

GSK3 and p53 - is there a link in Alzheimer's disease?
por: Proctor, Carole J, et al.
Publicado: (2010)

GSK-3β, a pivotal kinase in Alzheimer disease
por: Llorens-Marítin, María, et al.
Publicado: (2014)

GSK3β and Tau Protein in Alzheimer’s Disease and Epilepsy
por: Toral-Rios, Danira, et al.
Publicado: (2020)

GSK-3 and Tau: A Key Duet in Alzheimer’s Disease
por: Sayas, Carmen Laura, et al.
Publicado: (2021)

In silico discovery of SARS-CoV-2 main protease inhibitors from the carboline and quinoline database
por: Muhtar, Eldar, et al.
Publicado: (2021)

Effects of Herbal Compound (IMOD) on Behavior and Expression of Alzheimer's Disease Related Genes in Streptozotocin-Rat Model of Sporadic Alzheimer’s Disease
por: Bazazzadegan, Niloofar, et al.
Publicado: (2017)

Inhibition of lysosomal Ca(2+) signalling disrupts dendritic spine structure and impairs wound healing in neurons
por: Padamsey, Zahid, et al.
Publicado: (2017)

Quantification of 11 enzyme activities of lysosomal storage disorders using liquid chromatography-tandem mass spectrometry
por: Ohira, Mari, et al.
Publicado: (2018)

A Case of Minimally Progressive Prodromal Alzheimer’s Disease
por: Rosenbloom, Michael H., et al.
Publicado: (2023)

GSK3 Inhibits Macropinocytosis and Lysosomal Activity through the Wnt Destruction Complex Machinery
por: Albrecht, Lauren V., et al.
Publicado: (2020)

Impact of the COVID-19 pandemic on the standard of care for patients with lysosomal storage diseases: A survey of healthcare professionals in the Fabry, Gaucher, and Hunter Outcome Survey registries
por: Elstein, Deborah, et al.
Publicado: (2021)

Single-nucleotide polymorphisms of GSK3B, GAB2 and SORL1 in late-onset Alzheimer's disease: interactions with the APOE genotype
por: Izzo, Giselle, et al.
Publicado: (2013)

GSK3β Inhibition Ameliorates Atherosclerotic Calcification
por: Cai, Xinjiang, et al.
Publicado: (2023)

Outside-in induction of the IFITM3 trafficking system by infections, including SARS-CoV-2, in the pathobiology of Alzheimer’s disease
por: Vavougios, George D., et al.
Publicado: (2021)

Oxidative modification of lipoic acid by HNE in Alzheimer disease brain()
por: Hardas, Sarita S., et al.
Publicado: (2013)

Episodic Memory in Amnestic Behavioral Frontotemporal Dementia and Alzheimer’s Disease
por: Bussè, Cinzia, et al.
Publicado: (2023)

Substances use between early and later stages of the COVID-19 pandemic in Israel
por: Bonny-Noach, Hagit, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_o5gf7tctvok584k94qn9ifp94s